BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
REGN upcoming catalysts
Regeneron Pharmaceuticals: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 17 readout(s) and 5 FDA event(s). Subscribe to REGN (.ics).
Drugs: Cemiplimab, Fianlimab, Pembrolizumab, REGN7508, REGN9933, Dupilumab, REGN7999, Alirocumab, Apixaban, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil, Ravulizumab, Eculizumab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Semaglutide
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-03 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06421636 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participant | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | active not recruiting | 19 |
| 2026-12-29 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | Hypercholesterolemia | active not recruiting | 438 |
| 2027-01-15 est. | P3 | Regeneron Pharmaceuticals REGN | NCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has | Melanoma | active not recruiting | 1564 |
| 2027-02-09 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07175428 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Atrial Fibrillation (AF) | recruiting | 1200 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-08-19 | FDA approval | approved | REGENERON PHARMACEUTICALS, INC REGN | PASATRU | Approved 2026-08-19: PASATRU (BLA761508 ORIG1) |
| 2026-04-22 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | DUPIXENT | Approved 2026-04-22: DUPIXENT (BLA761055 SUPPL74) |
| 2026-04-02 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | EYLEA HD | Approved 2026-04-02: EYLEA HD (BLA761355 SUPPL5) |
| 2026-02-23 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | DUPIXENT | Approved 2026-02-23: DUPIXENT (BLA761055 SUPPL75) |
| 2025-11-19 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | EYLEA HD | Approved 2025-11-19: EYLEA HD (BLA761355 SUPPL10) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Overweight or Obesity | active not recruiting | 120 |
| 2026-11-13 est. | P1/P2 | Regeneron Pharmaceuticals REGN | NCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | active not recruiting | 548 |
| 2026-11-02 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Melanoma | active not recruiting | 151 |
| 2026-10-09 | P3 | Regeneron Pharmaceuticals REGN | NCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Atopic Dermatitis | completed | 880 |
| 2026-09-28 | P3 | Regeneron Pharmaceuticals REGN | NCT05133531 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH | Paroxysmal Nocturnal Hemoglobinuria | completed | 202 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-07-21 | P1/P2 | Regeneron Pharmaceuticals REGN | NCT07218770 A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | Active Noninfectious Uveitis Affecting the Posterior Segment | terminated | 1 |
| 2026-07-09 | P3 | Regeneron Pharmaceuticals REGN | NCT06548100 A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystroph | Generalized Lipodystrophy | completed | 9 |
| 2026-06-17 | P2 | Regeneron Pharmaceuticals REGN | NCT03888105 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Ot | B-cell Non-Hodgkin Lymphoma (B-NHL) | active not recruiting | 515 |
| 2026-06-16 | P2 | Regeneron Pharmaceuticals REGN | NCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weig | Obesity | completed | 1005 |
| 2026-06-08 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06384820 Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squ | Cutaneous Squamous Cell Carcinoma | withdrawn | |
| 2026-05-06 | P2 | Regeneron Pharmaceuticals REGN | NCT06593600 Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) | Postural Orthostatic Tachycardia Syndrome (POTS) | completed | 82 |
| 2026-05-02 | P3 | Regeneron Pharmaceuticals REGN | NCT07309432 Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy | Allergic Conjunctivitis | terminated | 24 |
| 2026-03-27 | P2 | Regeneron Pharmaceuticals REGN | NCT06299111 A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Cathe | Venous Thromboembolism | completed | 195 |
| 2026-03-12 | P3 | Regeneron Pharmaceuticals REGN | NCT05352672 Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally | Melanoma | active not recruiting | 1546 |
| 2026-02-23 | P2 | Regeneron Pharmaceuticals REGN | NCT05831176 A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side | Eosinophilic Gastritis (EoG); Eosinophilic Duodenitis (EoD); Eosinophilic Gastrointestinal Disease ( | active not recruiting | 22 |
| 2026-02-01 | P2 | Regeneron Pharmaceuticals REGN | NCT06608901 A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension | Sepsis-Induced Hypotension | completed | 76 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.